Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 3, 2007, Pages 383-389

  Ortiz, R A M ^a   Calafatti, S A ^a   Moraes, L A ^a   Deguer, M ^a   Ecclissato, C C ^a   Marchioretto, M A M ^a   Ribeiro, M L ^a   Bernasconi, G ^a   Pedrazzoli, Jr ^a  

^a UNIVERSIDADE SÃO FRANCISCO   (Brazil)

Author keywords

Clarithromycin; Helicobacter pylori; Lansoprazole; Peptic ulcer; Pharmacokinetics

Indexed keywords

CLARITHROMYCIN; LANSOPRAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STOMACH ACID SECRETION; TANDEM MASS SPECTROMETRY;

HELICOBACTER PYLORI;

EID: 33947162823     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2007000300014     Document Type: Article

References (25)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-69.
2. Penston JG, McColl KE. Eradication of Helicobacter pylon: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-243.
3. el-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylon infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 681-691.
4. el-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24.
5. Kuipers EJ. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther 1997; 11 (Suppl 1): 71-88.
6. Goddard AF, Spiller RC. The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Aliment Pharmacol Ther 1996; 10: 105-109.
7. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 5-12.
8. Benini L, Castellani G, Bardelli E, Sembenini C, Brentegani MT, Caliari S, et al. Omeprazole causes delay in gastric emptying of digestible meals. Dig Dis Sci 1996; 41: 469-474.
9. Peterson WL, Graham DY, Marshall B, Blaser MJ, Genta RM, Klein PD, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol 1993; 88: 1860-1864.
10. Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 189-204.
11. Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck DW. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39: 2078-2083.
12. Chu SY, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992; 36: 1147-1150.
13. Rowland M, Tozer TN. Clinical pharmacokinetics. Concepts and applications. 3rd edn. Baltimore: Williams & Wilkins; 1995.
14. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990; 28: 72-78.
15. Schall R, Hundt HK, Luus HG. Pharmacokinetic characteristics for extent of absorption and clearance in drug/drug interaction studies. Int J Clin Pharmacol Ther 1994; 32: 633-637.
16. Mainz D, Borner K, Koeppe P, Kotwas J, Lode H. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. J Antimicrob Chemother 2002; 50: 699-706.
17. Nakagawa Y, Itai S, Yoshida T, Nagai T. Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin, in comparison with erythromycin. Chem Pharm Bull 1992; 40: 725-728.
18. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255-259.
19. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999; 115: 19S-23S.
20. Mendonca S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter 2000; 5: 79-83.
21. Ecclissato C, Marchioretto MA, Mendonca S, Godoy AP, Guersoni RA, Deguer M, et al. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter 2002; 7: 53-59.
22. Langtry HD, Wilde MI. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54: 473-500.
23. Pedrazzoli J Jr, Calafatti SA, Ortiz RA, Dias FE, Deguer M, Mendes FD, et al. Transfer of clarithromycin to gastric juice is enhanced by omeprazole in Helicobacter pylori-infected individuals. Scand J Gastroenterol 2001; 36: 1248-1253.
24. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998; 3: 21-27.
25. 14C]clarithromycin in rat gastric tissue when administered with lansoprazole and amoxicillin. J Antimicrob Chemother 2002; 50: 285-288.